NCT06727370 Cognitive Screening in Lung Cancer Patients
| NCT ID | NCT06727370 |
| Status | Recruiting |
| Phase | — |
| Sponsor | European Institute of Oncology |
| Condition | Lung Disease |
| Study Type | OBSERVATIONAL |
| Enrollment | 200 participants |
| Start Date | 2024-01-10 |
| Primary Completion | 2025-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 200 participants in total. It began in 2024-01-10 with a primary completion date of 2025-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study aims to investigate the occurrence of cancer and adjuvant therapy-related cognitive impairment in patients with both NSCLC and SCLC. The primary endpoint measure will be the presence of cognitive impairment during the first year after enrollment through the administration of a comprehensive neuropsychological assessment.
Eligibility Criteria
Inclusion Criteria: * Small-cell and non-small-cell lung cancer (stage I, II, III, IV) * Age ≥ 18 years * Patients able to speak and read the local language(s) fluently * Acceptance and signature of informed consent Exclusion Criteria: * Age ≥ 70 * Presence of brain metastases * Patients with concomitant neurological or psychiatric disorders. * Patients undergoing brain radiotherapy * Previous diagnosis of lung cancer
Contact & Investigator
Gabriella Pravettoni
PRINCIPAL INVESTIGATOR
Istituto Europeo di Oncologia
Frequently Asked Questions
Who can join the NCT06727370 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 70 Years, studying Lung Disease. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06727370 currently recruiting?
Yes, NCT06727370 is actively recruiting participants. Contact the research team at gabriella.pravettoni@ieo.it for enrollment information.
Where is the NCT06727370 trial being conducted?
This trial is being conducted at Milan, Italy.
Who is sponsoring the NCT06727370 clinical trial?
NCT06727370 is sponsored by European Institute of Oncology. The principal investigator is Gabriella Pravettoni at Istituto Europeo di Oncologia. The trial plans to enroll 200 participants.